[Study on inhibitory effect of EGCG on Calcium oxalate nephrolithiasis in rats and its related mechanism].
In the study, the inhibitory effect of epigallocatechin gallate (EGCG) on Calcium oxalate nephrolithiasis and its possible mechanism were investigated. The rat Calcium oxalate nephrolithiasis model was induced through the combined oral administration of ethylene glycol and ammonium chloride, which was intervened with EGCG. Rat blood samples were collected to detect blood creatinine (Cr), blood urea nitrogen (BUN) and blood calcium. Rat urine samples were collected to observe and compare 24-hour urine volume, oxalic acid (Ox) and calcium in urine. Renal samples were collected to prepare tissue slices and observe the pathological changes in Calcium oxalate nephrolithiasis. The expression of osteopontin (OPN) in renal tissues was evaluated by Real-time PCR and Western blot. According to the results, compared with normal rats, rats in the nephrolithiasis model showed significant increases in Cr, BUN, urine Calcium, urine Ox and renal OPN expression (P < 0.05), but obvious decrease in 24-hour urine volume (P < 0.05); Compared with rats with nephrolithiasis, those processed with EGCG revealed remarkable declines in Cr, BUN, urine Calcium and urine Ox (P < 0.05), with significant rise in 24-hour urine volume (P < 0.05) in a concentration-dependent manner. Additionally, compared with the control group, nephrolithiasis rats showed significant pathological changes in Calcium oxalate calculus. After ECCG treatment, the renal pathological changes and OPN expression attenuated significantly in a concentration-dependent manner. The results showed that EGCG inhibits the formation of calcium oxalate nephrolithiasis in rats and shows a notable protective effect on renal functions.
Yong
Y
Zhou
Shuo
S
Wang
Chun-bo
CB
Tang
D000818:Animals; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000097:blood; D002129:Calcium Oxalate / Q000378:metabolism; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D053040:Nephrolithiasis / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D053495:Osteopontin / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D053495:Osteopontin; D002129:Calcium Oxalate; D002392:Catechin; D003404:Creatinine; C045651:epigallocatechin gallate; D002118:Calcium